in RILI treatment is related to the following aspects: (1) cancer pathways are the most enriched pathways for Houttuynia cordata Thunb.-based RILI treatment, with TP53, JUN, and VEGF as tumor-related bases, which are the core targets. The gene discussed is TP53; the disease is neoplasm.